Fortress Biotech Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Fortress Biotech Inc 's ROA in the second quarter of 2026?
Fortress Biotech Inc achieved a return on average assets (ROA) of 60.76 % in its second quarter of 2026, this is above FBIO's average return on assets of -50.29%.
Fortress Biotech Inc assets over the 12 months ending in its second quarter of 2026 are valued at $261 million

Despite the company's net income deteriorating, Fortress Biotech Inc was able to improve its ROA compared to the first quarter of 2026.

However, within the Healthcare sector 16 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 65, from total ROA ranking in the first quarter of 2026 at 4022.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	97.76 %	101.1 %	40.38 %	58.31 %	20.49 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	158	129	-33	-71	-107
Return On Assets (TTM)	60.76 %	58.2 %	-18.65 %	-43.53 %	-72.76 %
FBIO's Total Ranking	# 65	# 4022	# 3939	# 4268	# 4361
Total Assets (TTM) in million	316	358	187	181	160
Seq. Total Assets Change	-11.7 %	91.73 %	2.96 %	13.45 %	-10.21 %
Seq. Net Income Change	-99.56 %	1065.06 %	33.37 %	-	-

FBIO's 5 Years Annual ROA >> Back to FBIO Management Effectiveness >> Compare FBIO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 8
Sector	# 17
Overall	# 58

Return On Assets Statistics
High	Average	Low
60.88 %	-50.29 %	-84.72 %
(Jun 30 2026)		(Jun 30 2023)

Financial Statements
Fortress Biotech Inc 's Assets	$ 316 million	FBIO's Balance sheet
Fortress Biotech Inc 's Income	$ 1 million	Quarterly FBIO's Income Statement
FBIO's Income by Division		See FBIO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	40.38 %	-23.41 %	-37.14 %	-26.95 %	21.76 %
Total Assets in million	187	133	174	276	378
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-33	-121	-154	-214	-165
Annual Return On Assets	-17.62 %	-90.84 %	-88.74 %	-77.41 %	-43.57 %

FBIO's 5 Years Annual ROA >> Back to FBIO Management Effectiveness >> Compare FBIO ROA to its Competitors

More Return On Assets Ratios
FBIO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
FBIO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for FBIO's Competitors
Subscribers only: Roa for Fortress Biotech Inc 's Suppliers
Subscribers only: Return On Assets for FBIO's Customers

You may also want to know
FBIO's Roi	FBIO's Inventory Turnover Ratio	FBIO's Growth Rates	FBIO's Dividend Comparisons
	FBIO's Profitability Ratios	FBIO's Asset Turnover Ratio	FBIO's Dividend Growth
FBIO's Roe	FBIO's Valuation Ratios	FBIO's Financial Strength Ratios	FBIO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Kyntra Bio Inc	156.80 %
Vor Biopharma Inc	154.23 %
Glucotrack Inc	151.40 %
Capforce Inc	141.40 %
Protagenic Therapeutics Inc new	137.58 %
Elutia Inc	108.72 %
Silexion Therapeutics Corp	99.09 %
Arbutus Biopharma Corp	96.04 %
Pulmatrix Inc	94.81 %
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Oncotelic Therapeutics Inc	81.75 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %

Date modified: 2026-09-12T06:15:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.